Back
 OJRA  Vol.4 No.1 , February 2014
Atypical Femoral Fractures in a Patient with Continuous Decreasing BMD after Only 1.5 Years of Bisphosphonate Treatment
Abstract: Objective: Bisphosphonates were accepted first line treatment for osteoporosis. Long-term bisphosphonate treatment has been reported to be complicated with osteonecrosis of jaw (ONJ) and atypical fracture of femur. It is proposed to be the result of impaired remodeling of minor injury of bone. An atypical fracture occurs on a patient received only 1.5 years of bisphosphonate treatment with continuous decreasing bone mineral density. Case Presentation: This is a 53-year-old female Taiwanese. She has rheumatoid arthritis and has received long-term glucocorticoid treatment. Continuous decrease of bone mineral density in the serial BMD examination after alendronate treatment can be found. Thigh pain occurs after only 1.5 years of bisphosphonate treatment and it progresses to atypical fracture. Conclusions: Atypical fracture can occur in patients receive only short-term bisphosphonate treatment even BMD is still decreased after bisphosphonate treatment. Autoimmune disease, glucocorticoid treatment, Asian and female may be the possible risk factors.
Cite this paper: C. Hu, J. Renn, S. Yang and K. Lin, "Atypical Femoral Fractures in a Patient with Continuous Decreasing BMD after Only 1.5 Years of Bisphosphonate Treatment," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 4 No. 1, 2014, pp. 29-33. doi: 10.4236/ojra.2014.41004.
References

[1]   S. J. Gomberg, R. L. Wustrack, N. Napoli, C. D. Arnaud and D. M. Black, “Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy,” The Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 6, 2011, pp. 1627-1632. http://dx.doi.org/10.1210/jc.2010-2520

[2]   J. K. Lee, “Bilateral Atypical Femoral Diaphyseal Fractures in a Patient Treated with Alendronate Sodium,” International Journal of Rheumatic Diseases, Vol. 12, No. 2, 2009, pp. 149-154.

[3]   N. Kondo and T. Yoda, “Morphological Analysis of Bone Dynamics and Metabolic Bone Disease. Does Bisphosphonate Treatment Cause Severely Suppressed Bone Turnover (SSBT)?” Clinical Calcium, Vol. 21, No. 4, 2011, pp. 583-587.

[4]   T. Bamrungsong and C. Pongchaiyakul, “Bilateral Atypical Femoral Fractures after Long-Term Alendronate Therapy: A Case Report,” Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, Vol. 93, No. 5, 2010, pp. 620-624.

[5]   B. Abrahamsen, P. Eiken and R. Eastell, “Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis,” The Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 12, 2010, pp. 5258-5265. http://dx.doi.org/10.1210/jc.2010-1571

[6]   B. Abrahamsen, “Adverse Effects of Bisphosphonates,” Calcified Tissue International, Vol. 86, No. 6, 2010, pp. 421-435. http://dx.doi.org/10.1007/s00223-010-9364-1

[7]   J. Haschka, F. Kuhne, C. Muschitz, et al., “The 5-Year Follow-Up of a Cortical Stress Fracture Resulting in a Spontaneous Atypical Subtrochanteric Femoral Fracture in a Female Patient with Severe Osteoporosis and Bisphosphonate Therapy over 15 Years,” Wiener Klinische Wochenschrift, Vol. 123, No. 21-22, 2011, pp. 684-687. http://dx.doi.org/10.1007/s00508-011-0034-8

[8]   R. Armamento-Villareal, N. Napoli, K. Diemer, et al., “Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series,” Calcified Tissue International, Vol. 85, No. 1, 2009, pp. 37-44. http://dx.doi.org/10.1007/s00223-009-9263-5

[9]   C. K. Tjhia, S. M. Stover, D. S. Rao, C. V. Odvina and D. P. Fyhrie, “Relating Micromechanical Properties and Mineral Densities in Severely Suppressed Bone Turnover Patients, Osteoporotic Patients, and Normal Subjects,” Bone, Vol. 51, No. 1, 2012, pp. 114-122. http://dx.doi.org/10.1016/j.bone.2012.04.010

[10]   N. B. Watts and D. L. Diab, “Long-Term Use of Bisphosphonates in Osteoporosis,” The Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 4, 2010, pp. 1555-1565. http://dx.doi.org/10.1210/jc.2009-1947

[11]   E. Shane, D. Burr, B. Abrahamsen, et al., “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 29, No. 1, 2014, pp. 1-23.

[12]   W. D. Leslie, L. M. Lix, H. Johansson, et al., “Does Osteoporosis Therapy Invalidate FRAX for Fracture Prediction?” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 27, No. 6, 2012, pp. 1243-1251. http://dx.doi.org/10.1002/jbmr.1582

[13]   H. Dobnig, J. J. Stepan, D. B. Burr, et al., “Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated with Alendronate,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 24, No. 12, 2009, pp. 1998-2006. http://dx.doi.org/10.1359/jbmr.090527

[14]   S. Mori, “Calcium Pros and Cons: Long Term Use of Bisphosphonates. Bisphophonate Should Not Be Used for Long Term,” Clinical Calcium, Vol. 21, No. 10, 2011, pp. 1547-1551.

[15]   A. S. Neviaser, J. M. Lane, B. A. Lenart, F. Edobor-Osula and D. G. Lorich, “Low-Energy Femoral Shaft Fractures Associated with Alendronate Use,” Journal of Orthopaedic Trauma, Vol. 22, No. 5, 2008, pp. 346-350. http://dx.doi.org/10.1097/BOT.0b013e318172841c

[16]   S. Agarwal, S. Agarwal, P. Gupta, P. K. Agarwal, G. Agarwal and A. Bansal, “Risk of Atypical Femoral Fracture with Long-Term Use of Alendronate (Bisphosphonates): A Systemic Review of Literature,” Acta Orthopaedica Belgica, Vol. 76, No. 5, 2010, pp. 567-571.

[17]   S. J. Gallacher and T. Dixon, “Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review,” Calcified Tissue Internationa, Vol. 87, No. 6, 2010, pp. 469-484. http://dx.doi.org/10.1007/s00223-010-9420-x

[18]   B. A. Lenart, A. S. Neviaser, S. Lyman, et al., “Association of Low-Energy Femoral Fractures with Prolonged Bisphosphonate Use: A Case Control Study,” Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, Vol. 20, No. 8, 2009, pp. 1353-1362.

[19]   E. Donnelly, D. S. Meredith, J. T. Nguyen, et al., “Reduced Cortical Bone Compositional Heterogeneity with Bisphosphonate Treatment in Postmenopausal Women with Intertrochanteric and Subtrochanteric Fractures,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 27, No. 3, 2012, pp. 672-678. http://dx.doi.org/10.1002/jbmr.560

[20]   D. M. Black, A. V. Schwartz, K. E. Ensrud, et al., “Effects of Continuing or Stopping Alendronate after 5 Years of Treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial,” JAMA: The Journal of the American Medical Association, Vol. 296, No. 24, 2006, pp. 2927-2938. http://dx.doi.org/10.1001/jama.296.24.2927

[21]   D. Powell, C. Bowler, T. Roberts, et al., “Incidence of Serious Side Effects with Intravenous Bisphosphonate: A Clinical Audit,” QJM: Monthly Journal of the Association of Physicians, Vol. 105, No. 10, 2012, pp. 965-971. http://dx.doi.org/10.1093/qjmed/hcs112

[22]   G. A. Schmidt, K. E. Horner, D. L. McDanel, M. B. Ross and K. G. Moores, “Risks and Benefits of Long-Term Bisphosphonate Therapy,” American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, Vol. 67, No. 12, 2010, pp. 994-1001.

[23]   B. Abrahamsen and E. M. Clark, “Disentangling the Emerging Evidence around Atypical Fractures,” Current Rheumatology Reports, Vol. 14, No. 3, 2012, pp. 212-216. http://dx.doi.org/10.1007/s11926-012-0241-y

[24]   N. B. Watts, P. D. Miller, L. A. Kohlmeier, et al., “Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD with Teriparatide Treatment,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 24, No. 6, 2009, pp. 1125-1131. http://dx.doi.org/10.1359/jbmr.081256

[25]   C. M. Girgis, D. Sher and M. J. Seibel, “Atypical Femoral Fractures and Bisphosphonate Use,” The New England Journal of Medicine, Vol. 362, 2010, pp. 1848-1849. http://dx.doi.org/10.1056/NEJMc0910389

[26]   A. Giusti, N. A. Hamdy and S. E. Papapoulos, “Atypical Fractures of the Femur and Bisphosphonate Therapy: A Systematic Review of Case/Case Series Studies,” Bone, Vol. 47, No. 2, 2010, pp. 169-180. http://dx.doi.org/10.1016/j.bone.2010.05.019

[27]   E. Czerwinski, “Atypical Subtrochanteric Fractures after Long-Term Bisphosphonate Therapy,” Endokrynologia Polska, Vol. 62, No. 1, 2011, pp. 84-87.

[28]   M. Visekruna, D. Wilson and F. E. McKiernan, “Severely Suppressed Bone Turnover and Atypical Skeletal Fragility,” The Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 8, 2008, pp. 2948-2952. http://dx.doi.org/10.1210/jc.2007-2803

[29]   M. P. Somford, F. W. Draijer, B. J. Thomassen, P. M. Chavassieux, G. Boivin and S. E. Papapoulos, “Bilateral Fractures of the Femur Diaphysis in a Patient with Rheumatoid Arthritis on Long-Term Treatment with Alendronate: Clues to the Mechanism of Increased Bone Fragility,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 24, No. 10, 2009, pp. 1736-1740. http://dx.doi.org/10.1359/jbmr.090408

[30]   T. Braun and J. Zwerina, “Positive Regulators of Osteoclastogenesis and Bone Resorption in Rheumatoid Arthritis,” Arthritis Research & Therapy, Vol. 13, 2011, p. 235. http://dx.doi.org/10.1186/ar3380

[31]   T. Braun and G. Schett, “Pathways for Bone Loss in Inflammatory Disease,” Current Osteoporosis Reports, Vol. 10, 2012, pp. 101-108. http://dx.doi.org/10.1007/s11914-012-0104-5

[32]   A. L. Dolan, C. Moniz, H. Abraha and P. Pitt, “Does Active Treatment of Rheumatoid Arthritis Limit Disease-Associated Bone Loss?” Rheumatology, Vol. 41, No. 9, 2002, pp. 1047-1051. http://dx.doi.org/10.1093/rheumatology/41.9.1047

[33]   K. Iba, J. Takada, K. Sasaki, T. Wada and T. Yamashita, “Course of NTX Changes under Continuous Bisphosphonate Treatment in Cases of NTX Over-Reduction Due to Long-Term Treatment with Bisphosphonates,” Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association, Vol. 16, No. 1, 2011, pp. 71-76. http://dx.doi.org/10.1007/s00776-010-0008-0

[34]   S. Y. Kim, S. Schneeweiss, J. N. Katz, R. Levin and D. H. Solomon, “Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 26, No. 5, 2011, pp. 993-1001. http://dx.doi.org/10.1002/jbmr.288

[35]   B. Abrahamsen, P. Eiken and R. Eastell, “Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated with Alendronate: A Register-Based National Cohort Study,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 24, No. 6, 2009, pp. 1095-1102. http://dx.doi.org/10.1359/jbmr.081247

[36]   R. S. Yoon, J. S. Hwang and K. S. Beebe, “Long-Term Bisphosphonate Usage and Subtrochanteric Insufficiency Fractures: A Cause for Concern?” The Journal of Bone and Joint Surgery British Volume, Vol. 93, No. 10, 2011, pp. 1289-1295. http://dx.doi.org/10.1302/0301-620X.93B10.26924

[37]   D. M. Black, M. P. Kelly, H. K. Genant, et al., “Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur,” The New England Journal of Medicine, Vol. 362, 2010, pp. 1761-1771. http://dx.doi.org/10.1056/NEJMoa1001086

[38]   E. Shane, D. Burr, P. R. Ebeling, et al., “Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, Vol. 25, No. 11, 2010, pp. 2267-2294. http://dx.doi.org/10.1002/jbmr.253

[39]   J. C. Lo, S. Y. Huang, G. A. Lee, et al., “Clinical Correlates of Atypical Femoral Fracture,” Bone, Vol. 51, No. 1, 2012, pp. 181-184. http://dx.doi.org/10.1016/j.bone.2012.02.632

[40]   S. Sasaki, N. Miyakoshi, M. Hongo, Y. Kasukawa and Y. Shimada, “Low-Energy Diaphyseal Femoral Fractures Associated with Bisphosphonate Use and Severe Curved Femur: A Case Series,” Journal of Bone and Mineral Metabolism, Vol. 30, No. 5, 2012, pp. 561-567. http://dx.doi.org/10.1007/s00774-012-0358-0

[41]   D. E. Sellmeyer, “Atypical Fractures as a Potential Complication of Long-Term Bisphosphonate Therapy,” JAMA: The Journal of the American Medical Association, Vol. 304, No. 13, 2010, pp. 1480-1484. http://dx.doi.org/10.1001/jama.2010.1360

 
 
Top